Convalescent Plasma Therapy for Hospitalized Patients With COVID-19

• Status: Recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Plasma from donors who have recovered from coronavirus disease 2019 (COVID-19) contain antibodies to SARS-CoV-2 and may be a potential therapy for hospitalized patients with COVID-19. The efficacy of high-titer convalescent plasma for COVID-19, however, still unclear. The present study aims to evaluate the efficacy and safety of using convalescent plasma for treating hospitalized patients with COVID-19.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tânia Portella Costa
• Collaborators: Centro de Hematologia e Hemoterapia do Paraná - Hemepar; Fundação Oswaldo Cruz, Instituto Carlos Chagas, ICC Paraná; Science Valley Research Institute

Criteria

Inclusion Criteria:

• Hospitalized patients aged ≥18 years.

• Confirmed diagnosis of COVID-19 by RT-PCR or antigen test in respiratory samples.

• Time between symptom onset and inclusion ≤ 7 days.

• Enrolled within 5 days of hospitalization.

• Sign the consent form.

Exclusion Criteria:

• Contraindication to transfusion due to inability to tolerate additional fluid, such as due to decompensated congestive heart failure.

• History of previous severe allergic reactions to transfused blood products.

• Limiting comorbidity for administering the therapies provided for in this protocol in the opinion of the investigator.

• Not currently enrolled another interventional clinical trial of COVID-19 treatment.

• Critically ill patient with COVID-19 being treated in intensive care.